Associated Papers
Comparative Analysis of a Dual DNA-RNA Panel and a DNA-Only Panel for Sarcoma: Real-World Data From a Nationwide Genomic Database.
Nakata E et al.
Cancer Science, 2026
Novel KIT mutation, D816_N819delinsll, in a patient with systemic mastocytosis: a case report.
Juratli HA et al.
Virchows Archiv : an International Journal of Pathology, 2025
Computational modeling of human genetic variants in mice.
Dong K et al.
Biorxiv : the Preprint Server for Biology, 2025
Avapritinib monotherapy induces rapid and deep remission of heavily treated, KIT D816H-mutated t(8;21) acute myeloid leukemia, a case report and literature review.
Getz TM et al.
Annals of Hematology, 2025
Clinicopathological characteristics of progressive gastrointestinal stromal tumors and heterogeneity analyses of secondary mutations.
Li J et al.
The Oncologist, 2025
Real-World Evidence of the Prevalence of Driver Mutations in Anorectal Melanoma.
Jutten E et al.
Molecular Diagnosis & Therapy, 2025
Oncogenic composite mutations can be predicted by co-mutations and their chromosomal location.
Küçükosmanoglu A et al.
Molecular Oncology, 2024
Therapeutic advances of targeting receptor tyrosine kinases in cancer.
Tomuleasa C et al.
Signal Transduction and Targeted Therapy, 2024
Standing in the canine precision medicine knowledge gap: Improving annotation of canine cancer genomic biomarkers through systematic comparative analysis of human cancer mutations in COSMIC.
Sakthikumar S et al.
Veterinary and Comparative Oncology, 2023
Novel Molecular Therapies and Genetic Landscape in Selected Rare Diseases with Hematologic Manifestations: A Review of the Literature.
Ręka G et al.
Cells, 2023
c-Kit Receptors as a Therapeutic Target in Cancer: Current Insights.
Abdellateif MS et al.
Oncotargets and Therapy, 2023
Somatic mutation distribution across tumour cohorts provides a signal for positive selection in cancer.
Boström M et al.
Nature Communications, 2022
Systemic Mastocytosis and Other Entities Involving Mast Cells: A Practical Review and Update.
El Hussein S et al.
Cancers, 2022
Broad spectrum of regorafenib activity on mutant KIT and absence of clonal selection in gastrointestinal stromal tumor (GIST): correlative analysis from the GRID trial.
Jeffers M et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2022
Melanoma Targeted Therapies beyond BRAF-Mutant Melanoma: Potential Druggable Mutations and Novel Treatment Approaches.
Khaddour K et al.
Cancers, 2021
Pathogenic and diagnostic relevance of KIT in primary mast cell activation disorders.
Muñoz-González JI et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology, 2021
KIT and Melanoma: Biological Insights and Clinical Implications.
Pham DDM et al.
Yonsei Medical Journal, 2020
Prognostic model for patient survival in primary anorectal mucosal melanoma: stage at presentation determines relevance of histopathologic features.
Nagarajan P et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc, 2020
Combination of pembrolizumab and imatinib in a patient with double KIT mutant melanoma: A case report.
Abdou Y et al.
Medicine, 2019
Oncologist uptake of comprehensive genomic profile guided targeted therapy.
Nesline MK et al.
Oncotarget, 2019
Clinical mutational profiling and categorization of BRAF mutations in melanomas using next generation sequencing.
Lokhandwala PM et al.
Bmc Cancer, 2019
SF3B1, NRAS, KIT, and BRAF Mutation; CD117 and cMYC Expression; and Tumoral Pigmentation in Sinonasal Melanomas: An Analysis With Newly Found Molecular Alterations and Some Population-Based Molecular Differences.
Wroblewska JP et al.
The American Journal of Surgical Pathology, 2019
Computational analysis reveals histotype-dependent molecular profile and actionable mutation effects across cancers.
Heim D et al.
Genome Medicine, 2018
Autosomal dominant progressive hyperpigmentation and lentigines in a Japanese pedigree due to a missense mutation near the C-terminus of KIT.
Takeichi T et al.
The British Journal of Dermatology, 2018
PIK3CA mutation is a favorable prognostic factor in esophageal cancer: molecular profile by next-generation sequencing using surgically resected formalin-fixed, paraffin-embedded tissue.
Yokota T et al.
Bmc Cancer, 2018
Integrative omics analyses broaden treatment targets in human cancer.
Sengupta S et al.
Genome Medicine, 2018
The clinical significance of c-Kit mutations in metastatic oral mucosal melanoma in China.
Ma X et al.
Oncotarget, 2017
Testing and clinical implications for non-V600 BRAF mutations in metastatic NRASmt melanoma.
Richtig G et al.
The British Journal of Dermatology, 2017
NF1-mutated melanoma tumors harbor distinct clinical and biological characteristics.
Cirenajwis H et al.
Molecular Oncology, 2017
Mutation scanning of BRAF, NRAS, KIT, and GNAQ/GNA11 in oral mucosal melanoma: a study of 57 cases.
Lyu J et al.
Journal of Oral Pathology & Medicine : Official Publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology, 2016
Germline mutations of KIT in gastrointestinal stromal tumor (GIST) and mastocytosis.
Ke H et al.
Cell & Bioscience, 2016
Phase II Trial of Nilotinib in Patients With Metastatic Malignant Melanoma Harboring KIT Gene Aberration: A Multicenter Trial of Korean Cancer Study Group (UN10-06).
Lee SJ et al.
The Oncologist, 2015
Mastocytosis: a mutated KIT receptor induced myeloproliferative disorder.
Chatterjee A et al.
Oncotarget, 2015
Oncogenic mutations in melanomas and benign melanocytic nevi of the female genital tract.
Tseng D et al.
Journal of the American Academy of Dermatology, 2014
Mastocytosis associated with a rare germline KIT K509I mutation displays a well-differentiated mast cell phenotype.
Chan EC et al.
The Journal of Allergy and Clinical Immunology, 2014
The FBXO4 tumor suppressor functions as a barrier to BRAFV600E-dependent metastatic melanoma.
Lee EK et al.
Molecular and Cellular Biology, 2013
Molecular characterization of two novel KIT mutations in patients with piebaldism.
Wasag B et al.
Journal of Dermatological Science, 2012
Anorectal melanoma with a KIT-activating mutation, which is a target for tyrosine kinase inhibitor.
Itoh M et al.
International Journal of Clinical Oncology, 2011
Novel, activating KIT-N822I mutation in familial cutaneous mastocytosis.
Wasag B et al.
Experimental Hematology, 2011
V559A and N822I double KIT mutant melanoma with predictable response to imatinib?
McDonnell K et al.
Pigment Cell & Melanoma Research, 2011
Correlation between KIT expression and KIT mutation in melanoma: a study of 173 cases with emphasis on the acral-lentiginous/mucosal type.
Torres-Cabala CA et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc, 2009
Novel R634W c-kit mutation identified in familial mastocytosis.
Pollard WL et al.
Pediatric Dermatology, 0
Lack of Response to Imatinib in Melanoma Carrying Rare KIT Mutation p.T632I.
Orlova KV et al.
Case Reports in Oncology, 0